Familial atrial fibrillation is associated with numerous genetic variants in ion channels and structural genes, though translating these findings into personalized therapies remains challenging.
Atrial fibrillation (AF) is the most common clinical tachyarrhythmia. In Europe, AF is expected to reach a prevalence of 18 million by 2060. This estimate will increase hospitalization for AF to 4 million and 120 million outpatient visits. Besides being an independent risk factor for mortality, AF is also associated with an increased risk of morbidities. Although there are many well-defined risk factors for developing AF, no identifiable risk factors or cardiac pathology is seen in up to 30% of the cases. The heritability of AF has been investigated in depth since the first report of familial atrial fibrillation (FAF) in 1936. Despite the limited value of animal models, the advances in molecular genetics enabled identification of many common and rare variants related to FAF. The importance of AF heritability originates from the high prevalence of lone AF and the lack of clear understanding of the underlying pathophysiology. A better understanding of FAF will facilitate early identification of people at high risk of developing FAF and subsequent development of more effective management options. In this review, we reviewed FAF epidemiological studies, identified common and rare variants, and discussed their clinical implications and contributions to developing new personalized therapeutic strategies.
Ragab et al. (Fri,) conducted a review in Familial Atrial Fibrillation. Familial atrial fibrillation is associated with numerous genetic variants in ion channels and structural genes, though translating these findings into personalized therapies remains challenging.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: